The same technology that enables a bullet train to travel at speeds up to 200 mph without touching its rails now keeps a failing heart pumping-;and in the near future, it will do so via a wireless power connection.
Veracyte Acquires C2i Genomics for $70M, Expanding into Minimal Residual Disease Detection
What You Should Know: – Veracyte, Inc. (Nasdaq: VCYT), a cancer diagnostics company acquires C2i Genomics, Inc., a pioneer in minimal residual disease (MRD) detection.